|
Stomach Carcinoma
|
0.400 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results overall suggest that amplification of the c-met gene might participate in carcinogenesis and progression of stomach cancer, especially scirrhous type stomach carcinoma.
|
1333188 |
1992 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The TPR-MET oncogenic rearrangement is present and expressed in human gastric carcinoma and precursor lesions.
|
2052572 |
1991 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that increased levels of co-amplification of MYC and MET correlate with enhanced growth potential in this case of gastric carcinoma.
|
7664243 |
1995 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The presence of TPR-MET mRNA was determined in gastric tissue from 19 patients with gastric carcinoma and in the gastric mucosa of 18 first-degree relatives without gastric carcinoma and in the gastric mucosa of 18 first-degree relatives without gastric carcinoma using a nested reverse transcriptase-polymerase chain reaction (RT-PCR) and Southern blot analysis.
|
10760755 |
2000 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The presence of c-MET mRNA was correlated with T stage (P = 0.025), lymph node metastasis (P = 0.036), distant metastasis (P = 0.031), and stage of the stomach cancer (P = 0.023).
|
11966534 |
2002 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here we show that BFB cycles drive the intrachromosomal amplification of the MET oncogene in a human gastric carcinoma.
|
12086891 |
2002 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer.
|
12620387 |
2003 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of gastrin and c-met protein was associated (P<0.01), but no significant difference was found on the changes of gastrin, c-met and c-erbB2 expression in gastric cancer with tumor stage, grade of differentiation or tumor type.
|
14719064 |
2004 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recent studies show that the presence of c-Met gene amplification is predictive for selective c-Met TK inhibitors in gastric cancer and lung cancer.
|
18395971 |
2008 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This study assessed the incidence of MET expression and gene amplification in tumors of Western patients with gastric cancer.
|
21393565 |
2011 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target.
|
21424128 |
2011 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, qPCR revealed approximately 10% of white patients with gastric cancer harboring MET CNG of five or more copies.
|
22042954 |
2011 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Also, the prognostic role of MET indicates that anti-MET therapy is a very promising modality in adjuvant treatment for gastric cancer.
|
22644302 |
2012 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therapeutic strategies that target the tyrosine kinase MET hold promise for gastric cancer, but the mechanism underlying the antitumor activity of such strategies remains unclear.
|
22729845 |
2012 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The median MET copy number in 266 cases of gastric cancer was 1.7, with a range of 0.41 to 21.3.
|
23327903 |
2013 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate methods for assessing MET overexpression in gastric cancer, we conducted immunohistochemistry using a new anti-Total MET monoclonal antibody in a single-institution cohort of 495 patients.
|
23807774 |
2013 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multivariate analysis revealed that MACC-1 and c-MET may be independent prognostic indexes of gastric carcinoma (P < 0.01).
|
23812675 |
2013 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer.
|
24118504 |
2013 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
C-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis.
|
24223894 |
2013 |
|
Stomach Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The findings from present study indicated that higher MET gene amplification and expression in gastric cancer was an indicator of poor prognosis.
|
24416238 |
2014 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study aimed to explore the molecular segmentation of several known therapeutics targets, human epidermal growth factor receptor 2 (HER2), MET and fibroblast growth factor receptor 2 (FGFR2), within GC using clinically approved or investigational kits and scoring criteria.
|
24518603 |
2014 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-34a may act as a potential tumour suppressor in gastric cancer and is associated with the mechanisms of gastric cancer metastasis; miR-34a can inhibit gastric cancer tumourigenesis by targeting PDGFR and MET through the PI3K (phosphoinositide 3-kinase)/Akt pathway.
|
24837198 |
2014 |
|
Stomach Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
MET rs40239 may serve as a prognostic biomarker in locoregional gastric cancer.
|
25203738 |
2014 |
|
Stomach Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, this study suggests that MET mRNA expression assessed by RNA ISH could be useful as a potential marker to identify MET oncogene-addicted GC.
|
25364819 |
2014 |